摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-醛基吲唑 | 5235-10-9

中文名称
3-醛基吲唑
中文别名
1H-吲唑-3-甲醛
英文名称
1H-indazole-3-carboxaldehyde
英文别名
1H-indazole-3-carbaldehyde;2H-indazole-3-carbaldehyde
3-醛基吲唑化学式
CAS
5235-10-9
化学式
C8H6N2O
mdl
MFCD04972468
分子量
146.148
InChiKey
VXOSGHMXAYBBBB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    131-132 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
  • 沸点:
    358.3±15.0 °C(Predicted)
  • 密度:
    1.368±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    45.8
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险类别码:
    R36/37/38
  • 海关编码:
    2933990090
  • 安全说明:
    S26,S36/37/39
  • 危险标志:
    GHS07
  • 危险性描述:
    H302
  • 危险性防范说明:
    P280,P305+P351+P338

SDS

SDS:c98c17d650c69888e4af51272d637a22
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1H-Indazole-3-carbaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1H-Indazole-3-carbaldehyde
CAS number: 5235-10-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6N2O
Molecular weight: 146.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    吲唑-3-羧酸 1H-Indazole-3-carboxylic acid 4498-67-3 C8H6N2O2 162.148
    3-羟甲基吲唑 (1H-indazol-3-yl)methanol 64132-13-4 C8H8N2O 148.164
    N-甲氧基-n-甲基-1H-吲唑-3-羧酰胺 N-methoxy-N-methyl-1H-indazole-3-carboxamide 351457-12-0 C10H11N3O2 205.216
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    3-乙酰基吲唑 1-(1H-indazol-3-yl)ethanone 4498-72-0 C9H8N2O 160.175
    1-甲基-1H-吲唑-3-甲醛 1-methyl-1H-indazole-3-carbaldehyde 4002-83-9 C9H8N2O 160.175
    1H-吲唑-3-乙腈 2-(1H-indazol-3-yl)acetonitrile 101714-15-2 C9H7N3 157.175
    —— 3-(difluoromethyl)-1H-indazole 1415739-85-3 C8H6F2N2 168.146
    (1H-吲唑-3-基)-N,N-二甲基甲胺 (1H-indazol-3-ylmethyl)-dimethyl-amine 142910-86-9 C10H13N3 175.233
    —— (2E)-3-(1H-indazol-3-yl)-2-propenoic acid 842132-13-2 C10H8N2O2 188.186
    —— N-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole-3-carboxaldehyde 1346152-32-6 C14H20N2O2Si 276.41

反应信息

  • 作为反应物:
    描述:
    3-醛基吲唑manganese(IV) oxide 作用下, 以 二氯甲烷 为溶剂, 反应 9.5h, 生成 3-乙酰基吲唑
    参考文献:
    名称:
    发现新型吲唑作为有效和选择性的 PI3Kδ 抑制剂,对治疗肝细胞癌具有高疗效
    摘要:
    PI3Kδ 抑制剂已被开发用于治疗 B 细胞恶性肿瘤以及炎症和自身免疫性疾病。然而,它们在肝细胞癌 (HCC) 等实体瘤中的治疗作用却鲜有报道。因此,非常需要开发具有新化学类型和治疗的强效和选择性PI3Kδ抑制剂。通过支架跳跃策略,吲唑首次被描述为螺旋桨形PI3Kδ抑制剂的核心结构。共设计和制备了 26 种吲唑衍生物,用于鉴定具有良好异构体选择性、PK 曲线和效力的新型化合物9x 。与 Idelalisib 和索拉非尼相比,药效学 (PD) 研究表明,9x在 HCC 细胞系和异种移植模型中表现出卓越的功效,并且机制研究表明,9x强烈抑制下游 AKT 途径,从而在 HCC 模型中诱导随后的凋亡细胞死亡。因此,这项工作为 PI3Kδ 抑制剂的新结构设计提供了一种新的有效治疗 HCC 的小分子。
    DOI:
    10.1021/acs.jmedchem.1c01520
  • 作为产物:
    描述:
    3-羟甲基吲唑 在 manganese dioxide 作用下, 以 乙二醇二甲醚 为溶剂, 反应 1.25h, 以2.02 g of 1H-indazole-3-carboxaldehyde are thus obtained in the form of a yellow powder的产率得到3-醛基吲唑
    参考文献:
    名称:
    Benzimidazoles
    摘要:
    本发明涉及一般式(Ix)的生理活性化合物及含有这种化合物的组合物,以及它们的前药、药学上可接受的盐和溶剂化物,还涉及在式(Ix)范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质,特别是抑制激酶的能力。
    公开号:
    US20060014756A1
点击查看最新优质反应信息

文献信息

  • [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
    申请人:DAINIPPON SUMITOMO PHARMA CO
    公开号:WO2012169649A1
    公开(公告)日:2012-12-13
    The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]
    本发明涉及一种新型吲唑基或吡咯吡啶基衍生物,由下面的式(1)表示,该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用,并且包括含有该衍生物的药物组合物。式(1)[其中每个取代基如权利要求1所定义]
  • [EN] HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT ET PROCÉDÉS POUR LEUR UTILISATION
    申请人:ABBVIE INC
    公开号:WO2016044777A1
    公开(公告)日:2016-03-24
    Compounds having a structure of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R3c, R4a, R4b, R5, R6, Z and X are as defined herein are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    提供具有公式I结构或其立体异构体、互变异构体或药学上可接受的盐的化合物,其中R1、R2a、R2b、R3a、R3b、R3c、R4a、R4b、R5、R6、Z和X如本文所定义。还提供包含这些化合物的药物组合物以及通过给予这些化合物治疗各种HAT相关病症或疾病,包括癌症的方法。
  • [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:VIIV HEALTHCARE UK NO 5 LTD
    公开号:WO2021070054A1
    公开(公告)日:2021-04-15
    Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    化合物及其药用可接受的盐,以及用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法已列出。
  • [EN] VIRAL REPLICATION INHIBITORS<br/>[FR] INHIBITEURS DE REPLICATION VIRALE
    申请人:UNIV LEUVEN KATH
    公开号:WO2013045516A1
    公开(公告)日:2013-04-04
    The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    本发明涉及一系列新化合物,通过使用这些新化合物来预防或治疗动物的病毒感染的方法,以及将这些新化合物用作药物,更好地用于治疗或预防病毒感染,特别是感染RNA病毒,更特别是感染属于黄病毒科的病毒,更特别是感染登革病毒。本发明还涉及这些新化合物的药物组合或混合制剂,用作药物的组合或制剂,更好地用于预防或治疗病毒感染。该发明还涉及这些化合物的制备方法。
  • Thiocyanate radical mediated dehydration of aldoximes with visible light and air
    作者:Yong-Liang Ban、Jian-Ling Dai、Xiao-Ling Jin、Qing-Bao Zhang、Qiang Liu
    DOI:10.1039/c9cc05354a
    日期:——
    We developed a new means of activating aldoximes by an in situ generated thiocyanate radical from ammonium thiocyanate and molecular oxygen at room temperature. With a catalytic amount of organic dye aizenuranine as the photocatalyst, the dehydration of aldoximes proceeds smoothly under visible light irradiation, providing a simple to handle, excellent functional group tolerance, and metal-free protocol
    我们开发了一种通过在室温下从硫氰酸铵和分子氧中原位生成的硫氰酸根来活化醛肟的新方法。用催化量的有机染料壬酸鸟嘌呤作为光催化剂,醛肟的脱水在可见光照射下平稳进行,提供了简单的操作,优异的官能团耐受性和适用于多种腈的无金属方案。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台